Navigation Links
Novavax Announces Poster Presentation at the 47th Annual Meeting of the IDSA
Date:10/29/2009

ROCKVILLE, Md., Oct.29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that its abstract has been selected for poster presentation at the Infectious Diseases Society of America (IDSA) 47th Annual meeting being held in Philadelphia, Pennsylvania from October 29 - November 1, 2009.

Poster presentation: "Safety and Immunogenicity of a Recombinant Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Healthy Adults", Penny Heaton, M.D., Maria Allende, M.D., Kathy Lenhard, R.N., Mike Massare, PhD., and Mark Wolff, PhD. Saturday October 31, 2009 12:30 pm to 2:00 pm., Pennsylvania Convention Center, Poster Hall A.

About the 47th Annual Meeting of the IDSA

This conference will showcase abstract presentations containing outstanding, noteworthy science; and expanded roster of challenging interactive sessions; symposia on management of difficult pathogens, such as MRSA, Clostridium difficle, and drug-resistant mycobacteria, gram-negative bacillia and fungi; and the promises and challenges of new vaccines. The Special Plenary Session and Named Lectures will highlight important advancements as well as challenges in the world of infectious diseases. Additional information is available at www.idsociety.org.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP -based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The Company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com

SOURCE Novavax, Inc.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... , ... Thirty-six startup companies in University City and Center City have been ... Economic Development in 2016 as part of the Keystone Innovation Zone (KIZ) Tax Credit ... and represent the highest number of awards to the largest number of companies in ...
(Date:1/18/2017)... Jan. 18, 2017  Caris Life Sciences, a ... Foundation, the largest private funder of pancreatic cancer ... evaluating the impact of immunotherapy in the treatment ... enrollment services to identify potential trial candidates based ... treating physicians and study investigators. The Lustgarten Foundation ...
(Date:1/17/2017)... ... January 17, 2017 , ... LGC Maine Standards ... VALIDATE® SP2 calibration verification / linearity test kit. VALIDATE® SP2 evaluates Albumin, C-reactive ... SP2 kit is prepared using the CLSI recommended “equal delta” method for linearity ...
(Date:1/17/2017)... 2017  An international team of researchers from ... Boniface Hospital Albrechtsen Research Centre/University of Manitoba have ... health need affecting nearly one in 15 Americans. ... their results identify small molecule drugs with neuroprotective ... injury in animal models of metabolic, chemical and ...
Breaking Biology Technology:
(Date:12/20/2016)... 2016   Valencell , the leading innovator ... STMicroelectronics (NYSE: STM), a global semiconductor leader serving ... today the launch of a new, highly accurate ... includes ST,s compact SensorTile turnkey multi-sensor ... sensor system. Together, SensorTile and Benchmark deliver the ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December 15, ... global financial services provider, today announced an agreement with NuData ... biometrics, to join forces. The partnership will enable clients to ... in compliance with local data protection regulation. ... In order to provide ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
Breaking Biology News(10 mins):